Like other neoplasms, early detection is crucial, and prostate-specific antigen (PSA) testing is a common screening method, with newer biomarkers such as PHI and TMPRSS2-ERG fusion genes gaining traction 154,155. Here, KLK3 is linked to neoplasm.